Found 9 clinical trials
A research study for patients who have been diagnosed with multiple sclerosis
A research study for patients who have been diagnosed with multiple sclerosis
- 807 views
- 23 Nov, 2020
- 1 location
A Multicenter, Double-Blind, Placebo-Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving TECFIDERA® (Dimethyl Fumarate) Delayed-Release Capsules
A Multicenter, Double-Blind, Placebo-Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving TECFIDERA® (Dimethyl Fumarate
- 198 views
- 08 Nov, 2020
- 1 location
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (ARTIOS)
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
- 183 views
- 14 May, 2022
- 136 locations
Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy (LADIGAGA)
The primary objectives of the study are to assess the safety, tolerability and evidence of activity of 12 months oral treatment with TEFIDERA® in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
- 0 views
- 24 Mar, 2022
COVID-19 Booster Vaccination in Persons With Multiple Sclerosis
The success of the U.S. vaccination program against SARS-Cov-2 is shown by a dramatic drop in infection rates, hospitalizations and deaths.However, it appears that many persons who take medications that chronically suppress the immune system do not produce neutralizing antibodies to COVID-19 proteins in response to vaccination. This group includes …
- 0 views
- 22 Mar, 2022
- 1 location
Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP (TEC-ADHERE)
The primary objective is to compare oral dimethyl fumarate (DMF) persistence at six months in relapsing-remitting multiple sclerosis (RR-MS) participants initiating DMF with and without OroSEP
- 11 views
- 24 Apr, 2022
- 48 locations
Biogen Multiple Sclerosis Pregnancy Exposure Registry
during the eligibility window for that product. The Registry-specified Biogen MS products being studied are dimethyl fumarate, and Pegylated human interferon beta-1a. The secondary objective of the study
- 92 views
- 24 Jan, 2022
- 15 locations
Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera or Marovarex Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region
The purpose of this observational study is to evaluate the effectiveness, safety and health related quality of life of Generic DMF (Sclera or Marovarex , Hikma) in patients undergoing routine clinical care for RRMS in MENA Region
- 3 views
- 18 Sep, 2021
- 4 locations
Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication
The primary objective is to determine whether the use of immunomodulating medications have an impact on the ability to mount and sustain an immune response to SARS-CoV-2 spike protein following mRNA vaccination in patients with MS when compared to healthy controls not receiving immunomodulating medications. We hypothesize that the use …
- 0 views
- 09 May, 2022
- 1 location